Drug
SHR1459
SHR1459 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
4
100%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Other(2)
Detailed Status
unknown2
Completed2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 14 (100.0%)
Trials by Status
unknown250%
completed250%
Recent Activity
0 active trials
Showing 4 of 4
unknownphase_1
Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor
NCT03664297
completedphase_1
A Bioavailability Study of SHR1459 on Healthy Chinese Volunteers
NCT04395053
completedphase_1
Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)
NCT04649723
unknownphase_1
Safety, Tolerability and PK/PD of SHR1459 in Healthy Volunteers
NCT03668509
Clinical Trials (4)
Showing 4 of 4 trials
NCT03664297Phase 1
Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor
NCT04395053Phase 1
A Bioavailability Study of SHR1459 on Healthy Chinese Volunteers
NCT04649723Phase 1
Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)
NCT03668509Phase 1
Safety, Tolerability and PK/PD of SHR1459 in Healthy Volunteers
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4